Veracyte Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Veracyte, Inc (VCYT) PT Raised to $34 at Needham & Company
July 31, 2019 8:25 AM EDTNeedham & Company analyst Stephen Unger raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $34.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "Last night, VCYT reported solid 2Q19 results, with total revenues rising 32.5% y/y to $30.1M - $1.1M above our... More
Veracyte (VCYT) Tops Q2 EPS by 5c, Revenues Beat; Raises FY19 Revenue Guidance
July 30, 2019 5:01 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.05), $0.05 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $30.1 million versus the consensus estimate of $28.84 million.
Our strong second quarter performance was fueled by the growth of our products in three clinical indications, biopharmaceutical services revenue from milestone achievements and operational and financial discipline, said Bonnie Anderson, chairman and chief executive officer of Veracyte. In addition, we... More
